Skip to main content
Premium Trial:

Request an Annual Quote

Hologic Preliminary Q1 Revenues Increase 5 Percent

NEW YORK (GenomeWeb) – Hologic today announced that it expects its fiscal first quarter 2019 revenues to increase 5 percent year over year to $831 million from $791 million.

On a constant currency basis, revenues for the three months ended Dec. 29, 2018 are anticipated to be up almost 6 percent. The company had previously guided revenues for the period to a range of between $800 million and $815 million. The consensus Wall Street revenue estimate for the quarter is $811.3 million.

"We expect to post strong first quarter revenue well above our guidance range, driven by acceleration in our largest businesses — US breast health, international, and molecular diagnostics — all of which posted double-digit constant currency growth to start our year," Hologic Chairman, President, and CEO Steve MacMillan said in a statement.

By division, diagnostics revenues are expected to rise to $297 million from $285 million; diagnostics revenues excluding blood is expected to increase to $282 million from $272 million; and breast health revenues are anticipated to increase to $325 million from $288 million.

Hologic expects revenues from medical aesthetics to shrink, however, to $80 million from $91 million; gyn/surgical revenues to remain flat at $108 million; and skeletal health revenues to inch up to $21 million from $20 million.  

The company plans to report full financial results for fiscal Q1 on Jan. 30.

In early morning trading on the Nasdaq, Hologic's shares were up more than 3 percent to $40.48.